Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
54 results about "Solid organ transplantation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Definition of Solid Organ Transplant. Solid Organ Transplant means live-donor kidney transplants and transplants of the following organs from cadaveric donors: kidney, pancreas, liver, intestines, heart and lung, but not the transplantation of stem cells, bone marrow, peripheral blood or cord blood.
Real time imagining during solid organ transplant
Owner:STRYKER EUROPEAN OPERATIONS LIMITED
Real time vascular imaging during solid organ transplant
The invention provides methods and systems for imaging vessels in a subject. In certain embodiments the vessels may be associated with a solid organ transplant.
Owner:NOVADAG TECH INC
Methods and compositions for evaluating graft survival in a solid organ transplant recipient
ActiveUS20060246485A1Microbiological testing/measurementBiological testingOrgan transplantationProtein level
Methods are provided for evaluating a subject for graft survival, e.g., in terms of predicting graft survival, identifying the presence of a deleterious graft condition, such as CAN and DT, identifying the severity and class of acute rejection, etc, in a subject are provided. In practicing the subject methods, the expression of at least one gene in a sample from the subject, e.g., a blood or biopsy sample, is assayed, e.g., at the nucleic acid and / or protein level, to evaluate the subject. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Real time imaging during solid organ transplant
The invention provides methods and systems for imaging vessels in a subject. In certain embodiments the vessels may be associated with a solid organ transplant.
Owner:STRYKER CORP
Function Inhibitor of Effector Cell
InactiveUS20070270429A1Inhibit functioningBiocideOrganic chemistryAutoimmune conditionIslet cell transplantation
The present invention relates to a function inhibitor of an effector cell comprising a CCR5 antagonist. Since the function inhibitor of an effector cell comprising a CCR5 antagonist inhibits the function of effector cells which play an important role in formation of diseases and the like, it is effective for the prevention and / or treatment of, for example, a transplant rejection (e.g., rejection of a solid organ graft, rejection of islet cell transplantation in diabetes mellitus, graft-versus-host disease (GVHD), etc.), an autoimmune disease (e.g., arthritis, rheumatoid arthritis, multiple sclerosis, ulcerative colitis, etc.), an allergic disease (e.g., asthma, etc.), an ischemic disease (e.g., ischemia-reperfusion injury, etc.), cancer or a metastatic disease or the like.
Owner:ONO PHARMA CO LTD
HIF-1 Modulator Paint Formulation and Uses Thereof
ActiveUS20150196512A1Improve permeabilityGood sustained releaseBiocidePowder deliveryIron ChelatorMedicine
Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +2
Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
In its many embodiments, the present invention provides a novel class of bipiperidinyl compounds as inhibitors of the CCR5 receptors, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with CCR5 using such compounds or pharmaceutical compositions. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
Owner:SCHERING CORP
Method for obtaining immuno-suppressive dendritic cells
The present invention relates to methods for producing immuno-suppressive dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from autoimmune diseases, hypersensitivity diseases, rejection on solid-organ transplantation and / or Graft-versus-Host disease.
Owner:TRANSIMMUNE +1
Non-invasive early detection of solid organ transplant rejection by quantitative analysis of mixtures by deep sequencing of HLA gene amplicons using next generation systems
ActiveUS20140336056A1Microbiological testing/measurementLibrary member identificationOrgan transplant rejectionNon invasive
The invention is a method of detecting or assessing solid organ graft (transplant) rejection by detecting donor-specific HLA alleles in a blood sample of a graft (transplant) recipient. The invention further comprises a method of detecting the presence of maternal cells in a blood sample of an offspring.
Owner:THE SCRIPPS RES INST +1
Methods and compositions for evaluating graft survival in a solid organ transplant recipient
ActiveUS7741038B2Microbiological testing/measurementBiological testingReceptor for activated C kinase 1Gastroenterology
Methods are provided for evaluating a subject for graft survival, e.g., in terms of predicting graft survival, identifying the presence of a deleterious graft condition, such as CAN and DT, identifying the severity and class of acute rejection, etc, in a subject are provided. In practicing the subject methods, the expression of at least one gene in a sample from the subject, e.g., a blood or biopsy sample, is assayed, e.g., at the nucleic acid and / or protein level, to evaluate the subject. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Methods of detecting cell-free DNA in biological samples
PendingUS20200048713A1Increase coverageMicrobiological testing/measurementLibrary screeningCell freeHost response
The present disclosure is directed to methods of detecting cell-free DNA (cfDNA) in biological samples and using it to quantify organ damage and identify pathogens. In some aspects, the biological samples are from patients who have undergone solid-organ transplantation. The disclosure is also directed to methods of detecting and analyzing methylation patterns in cell-free DNA from organ transplant patients to identify the presence of pathogens as well as quantify contributing tissue proportions as a measurement of the host response.
Owner:CORNELL UNIVERSITY
Piperidine derivatives useful as ccr5 antagonists
Owner:MERCK SHARP & DOHME CORP
Method of treating diseases using kinase modulators
InactiveUS20190077856A1Stimulate immune responseReduce riskOrganic active ingredientsImmunoglobulins against growth factorsTransplant rejectionAutoimmune disease
Provided herein are methods of modulating immune response, including methods of treating a cancer or an infection using a combination of kinase modulators and immunotherapy that promotes immune response. Also provided herein are methods of treating an autoimmune disease or graft-versus-host disease, and methods of reducing the risk of solid organ transplant rejection using a combination of kinase modulators and immunosuppressive therapy.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT
Non-invasive early detection of solid organ transplant rejection by quantitative analysis of mixtures by deep sequencing of HLA gene amplicons using next generation systems
Owner:THE SCRIPPS RES INST +1
Method of immunomodulation
InactiveUS20060153843A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsFunctional activityResponder cell
The present invention relates generally to a method for modulating the activity of cells of the immune system, including stimulator and responder cells and to agents useful therefor. More particularly, the present invention relates to a method for preventing or down-regulating one or more functional activities of stimulator and responder cells such as, respectively, antigen-presenting cells and lymphocytes inter alia. The present invention further provides antibodies, which interact specifically with epitopes present on the surface of antigen-presenting cells and lymphocytes, resulting in depletion, down-regulation or destruction of targeted antigen-presenting cells and lymphocytes in vivo or in vitro. The instant invention further provides a method for modulating an immune response in a subject and, in particular, for down-regulating the immuno-activity of an allogeneic immuno-competent graft and / or the immune response of a recipient of a solid organ transplant. The ability to modulate stimulator and responder cell immuno-activity may be useful, inter alia, in a range of immuno-therapeutic and immuno-prophylactic treatments that benefit from immune suppression.
Owner:THE OF THE TRUSTEES OF THE SISTERS OF MERCY & QUEENSLAND
Cd44-Targeting for Reducing/Preventing Ischemia-Reperfusion-Injury
InactiveUS20070280930A1Easy to storePrevent and reduce injuryOrganic active ingredientsBiocideReperfusion injuryOrgan transplantation
The present invention relates to CD44 binding molecules, preferably anti-CD44 antibodies, and their use in methods for the prevention or reduction of ischemia-reperfusion injury in e.g. solid organ transplantation or in patients in shock. The invention further relates to methods wherein levels of soluble CD44 are determined in e.g. serum or urine as a prognostic factor for the risk of organ rejection.
Owner:ROUSCHOP KASPER MATHIAS ANTOON +1
Mobilization and collection of peripheral blood hematopoietic stem cells from deceased donors
PendingUS20210189344A1Reduce the risk of contaminationRespects dignityOrganic active ingredientsPeptide/protein ingredientsHuman cellOrgan transplanting
This invention describes new methods for the mobilization of human cells such as hematopoietic stem cells in bone marrow, and the subsequent collection of such cells from the peripheral blood of deceased donors. These methods produce quantities of hematopoietic stem cells that can be used in a multitude of possible applications without harming the deceased donor or the recovery of the deceased donor's organs for solid organ transplantation. The methods involve the administration of one or more mobilizing agents to mobilize bone marrow cells into the peripheral blood cells followed by the collection of cells via apheresis.
Owner:RGT UNIV OF CALIFORNIA
Methods of Treating CMV Retinitis by T Cell Therapy
ActiveUS20170128565A1Confer resistanceSenses disorderViral antigen ingredientsOrgan transplantationHuman patient
Disclosed herein are methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with HIV or has been the recipient of a solid organ transplant.
Owner:CORNELL UNIVERSITY +1
CCR5 antagonists useful for treating aids
Compounds of the formula or a pharmaceutically acceptable salt or isomer thereof, wherein:Q, X and Z are CH or N;R, R4-R7 and R13 are H or alkyl;R1 is H, alkyl, fluoroalkyl, R9-arylalkyl, R9-heteroarylalkyl, alkyl-SO2—, cycloalkyl-SO2—, fluoroalkyl-SO2—, R9-aryl-SO2—, R9-heteroaryl-SO2—, N(R22)(R23)—SO2—, alkyl-C(O)—, cycloalkyl-C(O)—, fluoroalkyl-C(O)—, R9-aryl-C(O)—, NH-alkyl-C(O)— or R9-aryl-NH—C(O)—;R2 is H and R3 is H, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, R9-aryl, R9-arylalkyl, R9-heteroaryl, or R9-heteroarylalkyl, and when X and Z are each CH, R3 is alkoxy, R9-aryloxy, R9-heteroaryloxy, alkylC(O)O—, alkylaminoC(O)O—, alkylC(O)NR13—, alkylOC(O)NR13— or alkylaminoC(O)NR13—;or R2 and R3 together are ═O, ═NOR10, ═N—NR11R12 or ═CH-alkyl;R8 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenymethyl, alpha-substituted benzyl or alpha-substituted heteroarylmethyl;R9-R12 are as defined;are disclosed for the treatment of HIV, solid organ transplant rejection, graft v. host disease, inflammatory diseases, atopic dermatitis, asthma, allergies or multiple sclerosis, as well as pharmaceutical compositions and combinations with antiviral or anti-inflammatory agents.
Owner:SCHERING CORP
Chimeric antigen receptor targeting HLA-A, coding gene, CAR-Tregs cell and preparation method and application thereof
ActiveCN112852748AImprove bindingInhibitory activityMammal material medical ingredientsImmunoglobulinsAntiendomysial antibodiesAntigen binding
The invention discloses a chimeric antigen receptor targeting HLA-A, a coding gene, a recombinant expression vector, a CAR-Tregs cell and a preparation method and application thereof. The chimeric antigen receptor comprises a signal peptide, an antigen binding structural domain, a hinge region, a transmembrane region, a costimulatory factor and an intracellular signal transduction domain. The antigen binding domain is a binding structural domain of an anti-HLA-A11 antibody or an anti-HLA-A33 antibody, and the CAR-Tregs cell is a Treg cell modified by a chimeric antigen receptor targeting HLA-A11 or HLA-A33, can inhibit specific immune response, and can be used for inhibiting rejection reaction after a solid organ transplantation operation.
Owner:CHENGDU SHIKANGMEI BIOTECHNOLOGY CO LTD
Non-invasive early detection of solid organ transplant rejection by quantitative analysis of HLA gene amplicons
InactiveUS20160017421A1Microbiological testing/measurementLibrary screeningSexual dysfunctionOrgan transplantation
The invention is a method of detecting or assessing solid organ graft (transplant) rejection and acute dysfunction—no rejection condition by detecting donor-specific HLA alleles in a blood sample of a graft (transplant) recipient.
Owner:THE SCRIPPS RES INST A PUBLIC BENEFIT NOT FOR PROFIT RES INST +1
Chimeric antigen receptor targeting HLA-A, encoding gene, CAR-Tregs cells, and preparation method and application of CAR-Tregs cells
ActiveCN111393533AImprove bindingInhibitory activityMammal material medical ingredientsBlood/immune system cellsAntiendomysial antibodiesAntigen binding
The invention discloses a chimeric antigen receptor targeting HLA-A, an encoding gene, a recombinant expression vector, CAR-Tregs cells, and a preparation method and application of the CAR-Tregs cells. The chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a hinge region, a transmembrane region, a co-stimulatory factor and an intracellular signal transduction domain;the antigen binding domain is a binding domain of an anti-HLA-A11 antibody or an anti-HLA-A33 antibody; the CAR-Tregs cells disclosed by the invention are Treg cells modified by the chimeric antigen receptor targeting HAL-A11 or HLA-A33, can inhibit specific immunoreaction and can be used for inhibition from solid organ transplantation postoperative rejection reaction.
Owner:成都仕康美生物科技有限公司
Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
PendingCN112074277AOrganic active ingredientsPeptide/protein ingredientsImmunocompetenceThymus Glands
Methods and compositions for promoting donor-specific tolerance and immunocompetence to a recipient of a solid organ transplant, by implanting an allogeneic solid organ in a recipient in need of a solid organ transplant and further comprising surgical implantation of a tissue-engineered allogeneic cultured postnatal thymus tissue product in the recipient of a solid organ from a donor.
Owner:DUKE UNIV
Methods of Treating Diseases Using Kinase Modulators
PendingUS20210379046A1Stimulate immune responseReduce riskOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsImmunologic disordersAutoimmune condition
Provided herein are methods of modulating immune response, including methods of treating a cancer or an infection using a combination of kinase modulators and immunotherapy that promotes immune response. Also provided herein are methods of treating an autoimmune disease or graft-versus-host disease, and methods of reducing the risk of solid organ transplant rejection using a combination of kinase modulators and immunosuppressive therapy.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT
Adoptive t-cell therapy for cmv infection and cmv-associated diseases
PendingCN112703195AReduce or eliminate the needPeptide librariesPeptide/protein ingredientsDiseaseCmv infections
Provided herein are immunogenic polypeptides, compositions, and methods related to the development of CMV-specific prophylactic and / or therapeutic immunotherapy based on T cell epitopes (e.g., CMV epitopes) that are recognized by cytotoxic T cells (CTLs) and can be employed in the prevention and / or treatment of CMV infection, reactivation, and / or disease (e.g., CMV-associated end organ disease), especially in solid organ transplant recipients.
Owner:COUNCIL OF THE QUEENSLAND INST OF MEDICAL RES
Compositions and methods for diagnosis and prediction of solid organ graft rejection
InactiveUS20190316198A1Microbiological testing/measurementOrgan transplantationOrgan transplant rejection
Owner:IMMUCOR GTI DIAGNOSTICS
Organ jacket and methods of use
ActiveUS9770472B1Prevent and reduce incidenceReduce painMammal material medical ingredientsCross-linkOrgan transplantation
An organ jacket fabricated from human birth tissue comprising at least one cross-linked amniotic membrane, or at least one cross-linked chorionic membrane, or at least one amniotic membrane, or at least one chorionic membrane, or any combination thereof. Methods of processing a membrane to form an organ jacket and methods of preventing graft rejection in solid organ transplantation and methods of reducing the incidence of acute and chronic rejection episodes after solid organ transplantation are also provided.
Owner:BIODLOGICS
HLA tissue matching and methods therefor
PendingCN111213210AMicrobiological testing/measurementBiostatisticsOrgan transplantingComputer analysis
Contemplated systems and methods use high-accuracy in silico HLA analysis to so establish a transplant match database suitable for transplantation, and particularly stem cell and solid organ transplant.
Owner:NANT HLDG IP LLC
Anti-cd40 antibodies for use in prevention of graft rejection
PendingUS20210079107A1Prevent graft rejectionPrevent rejectionImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntiendomysial antibodiesOrgan transplanting
The disclosure relates to methods, treatment regimens, uses, kits and therapies for preventing graft rejection in solid organ transplantation, by employing anti-CD40 antibodies.
Owner:NOVARTIS AG
Platform independent haplotype identification and use in ultrasensitive DNA detection
InactiveUS20200232033A1Improve accuracyHigh precisionMicrobiological testing/measurementDna detectionSolid organ transplantation
The present invention provides methods for analyzing blocks of closely spaced SNPs, or haplotypes for use in identification of the origin of DNA in a sample. The methods comprise aligning common alleles of a gene of interest and identifying a region containing a plurality of SNPs which is flanked by non-polymorphic DNA which can be used for primer placement. Any sequencing method, including next generation sequencing methods can then be used to determine the haplotypes in the sample with a lower limit of detection of at least 0.01%. These inventive methods are useful, for example, for identification of hematopoietic stem cell transplantation patients destined to relapse, microchimerism associated with solid organ transplantation, detection of solid organ transplant rejection by detecting donor DNA in recipient plasma, forensic applications, and patient identification.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com